Testosterone Replacement Therapy in Men With Hypogonadism and HIV/AIDS: Results From the TRiUS Registry

Blick, Gary; Khera, Mohit; Bhattacharya, Rajib; Kushner, Harvey; Miner, Martin

doi:10.3810/pgm.2013.03.2638

Cited by 15 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a general rule, any chronic (inflammatory) condition that puts one out of eustasis may lead to “sick gonadotroph syndrome” (Figure 2). 30 In this context, chronic pain and/or chronic opioid use can cause hypogonadism which can be successfully treated by testosterone gel 31. Patients can generally present with unexplained fatigue, depression, loss of libido, or erectile dysfunction (Table 1).…”

Section: Diagnosis Of Male Hypogonadismmentioning

confidence: 99%

Transdermal testosterone replacement therapy in men

Ullah¹,

Riche²,

Koch³

2014

DDDT

View full text Add to dashboard Cite

Androgen deficiency syndrome in men is a frequently diagnosed condition associated with clinical symptoms including fatigue, decreased libido, erectile dysfunction, and metabolic syndrome. Serum testosterone concentrations decline steadily with age. The prevalence of androgen deficiency syndrome in men varies depending on the age group, known and unknown comorbidities, and the respective study group. Reported prevalence rates may be underestimated, as not every man with symptoms of androgen deficiency seeks treatment. Additionally, men reporting symptoms of androgen deficiency may not be correctly diagnosed due to the vagueness of the symptom quality. The treatment of androgen deficiency syndrome or male hypogonadism may sometimes be difficult due to various reasons. There is no consensus as to when to start treating a respective man or with regards to the best treatment option for an individual patient. There is also lack of familiarity with treatment options among general practitioners. The formulations currently available on the market are generally expensive and dose adjustment protocols for each differ. All these factors add to the complexity of testosterone replacement therapy. In this article we will discuss the general indications of transdermal testosterone replacement therapy, available formulations, dosage, application sites, and recommended titration schedule.

show abstract

Section: Diagnosis Of Male Hypogonadismmentioning

confidence: 99%

Transdermal testosterone replacement therapy in men

Ullah¹,

Riche²,

Koch³

2014

DDDT

View full text Add to dashboard Cite

show abstract

“…Healthc. 2018; 5 (34), 2507-2511. DOI: 10.18410/jebmh/2018/517 BACKGROUND A wide spectrum of endocrine abnormalities is seen in HIV patients.…”

mentioning

confidence: 99%

Hypogonadism Among Hiv Infected Males and Its Correlation With Cd4 Count

Ranabir¹,

Pongener²,

Premita³

et al. 2018

jebmh

View full text Add to dashboard Cite

BACKGROUND After introduction of Highly Active Anti-Retroviral Therapy (HAART), the prevalence of hypogonadism among Human Immunodeficiency Virus (HIV) infected males is decreasing. MATERIALS AND METHODS Cross-sectional study was undertaken at ART centre of a medical Institute. The study recruited HIV infected males aged 18 to 65 years receiving ART. Patients with any debilitating chronic illness, diabetes mellitus, chronic smokers or alcoholic, currently on opioids or methadone were excluded. Androgen deficiency in aging male (ADAM) questionnaire was used to screen patients for possible presence of hypogonadism. Patients underwent biochemical evaluation for serum total testosterone (TT), luteinising hormone (LH) and CD4 count. Chi-squared test was used to compare different parameters. Pearson's correlation coefficient was used to assess any relationship between CD4 count, LH and testosterone. A p-value of <0.05 was considered statistically significant. RESULTS In the study 120 patients were evaluated. The mean age of the patients was 41.61 years. The mean BMI of the patients was 22.47 kg/m2. The mean duration of ART was 6.13 years and mean CD4 count was 442.63 cells/mm3. Hypogonadism was seen in 20 (23.3%) and majority (85.7%) had secondary hypogonadism. There was significant association between hypogonadism and CD4 count but no association was found with body mass index (BMI) and duration of ART. CONCLUSION Hypogonadism is seen in 23.3% of HIV infected males. Majority (85.7%) had secondary hypogonadism. There was significant association of hypogonadism with lower CD4 count.

show abstract

Testicular Dysfunction in Systemic Diseases

Sartorius,

Handelsman

2023

Andrology

View full text Add to dashboard Cite

Testosterone Replacement Therapy in Men With Hypogonadism and HIV/AIDS: Results From the TRiUS Registry

Cited by 15 publications

References 56 publications

Transdermal testosterone replacement therapy in men

Transdermal testosterone replacement therapy in men

Hypogonadism Among Hiv Infected Males and Its Correlation With Cd4 Count

Testicular Dysfunction in Systemic Diseases

Contact Info

Product

Resources

About